| abstract |
The present invention relates to an EGFR inhibitor having a structure of formula (I) and a preparation method therefor, a pharmaceutical composition containing the EGFR inhibitor, a use of the pharmaceutical composition as the EGFR inhibitor, a use of the pharmaceutical composition in treating and/or preventing cancers, tumors, or metastatic diseases at least partially related to an EGFR exon 20 insertion or deletion mutation, and in particular a use of the pharmaceutical composition in treating hyperproliferative diseases and induced cell death disorders. Substituents in formula (I) have the same definitions as those in the description. |